Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events. Topline data from the multiple ascending dose cohorts ...
SHANGHAI--(BUSINESS WIRE)--YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results